Introduction Alzheimer's disease and related dementias (ADRD) disproportionately impact
racial and ethnic minority and socioeconomically disadvantaged adults. Yet, these …

Clinical Alzheimer's disease (AD) trials currently face a critical shortfall of thousands of
eligible participants, which inflates the duration and cost of the clinical study as well as …

African-Americans are often not enthusiastic about participating in Alzheimer disease
research due to past exploitation from medical and public health studies. To assure …

Alzheimer disease (AD) research faces challenges to successful enrollment, especially to
clinical trials and biomarker studies. Failure to recruit the planned number of participants in a …

Introduction Ethnicity influences dementia etiology, prognosis, and treatment, while culture
shapes help‐seeking and care. Despite increasing population diversity in high‐income …

Importance Underrepresentation of many racial/ethnic groups in Alzheimer disease (AD)
clinical trials limits generalizability of results and hinders opportunities to examine potential …

African Americans experience a greater risk of Alzheimer disease (AD), but are
underrepresented in AD research. Our study examined barriers and facilitators of AD …

We describe the history, development, and success of the recruitment and screening
procedures used by researchers at the University of California, Davis Alzheimer's Disease …

Alzheimer's disease and related dementias (ADRDs) are a global crisis facing the aging
population and society as a whole. With the numbers of people with ADRDs predicted to rise …

Importance For informed decision making on diagnosis and treatment of dementia,
physicians and their patients rely on the generalizability of evidence from published studies …